Log in

NASDAQ:ALNY - Alnylam Pharmaceuticals Stock Price, Forecast & News

$117.74
-2.87 (-2.38 %)
(As of 12/15/2019 01:26 AM ET)
Today's Range
$117.05
Now: $117.74
$121.53
50-Day Range
$86.17
MA: $103.59
$124.28
52-Week Range
$60.27
Now: $117.74
$125.72
Volume557,589 shs
Average Volume917,812 shs
Market Capitalization$13.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.47
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALNY
CUSIP02043Q10
Phone617-551-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$74.91 million
Book Value$12.87 per share

Profitability

Net Income$-761,490,000.00
Net Margins-485.73%

Miscellaneous

Employees1,065
Market Cap$13.13 billion
Next Earnings Date2/6/2020 (Estimated)
OptionableOptionable

Receive ALNY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.


Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($2.17) by $0.25. The biopharmaceutical company earned $70.06 million during the quarter, compared to the consensus estimate of $57.14 million. Alnylam Pharmaceuticals had a negative net margin of 485.73% and a negative return on equity of 52.88%. Alnylam Pharmaceuticals's revenue was up 3284.5% compared to the same quarter last year. During the same period last year, the firm earned ($1.56) earnings per share. View Alnylam Pharmaceuticals' Earnings History.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Alnylam Pharmaceuticals.

What price target have analysts set for ALNY?

18 Wall Street analysts have issued 1-year target prices for Alnylam Pharmaceuticals' shares. Their forecasts range from $62.00 to $159.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $115.50 in the next twelve months. This suggests that the stock has a possible downside of 1.9%. View Analyst Price Targets for Alnylam Pharmaceuticals.

What is the consensus analysts' recommendation for Alnylam Pharmaceuticals?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alnylam Pharmaceuticals.

What are Wall Street analysts saying about Alnylam Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Alnylam incurred narrower-than-expected loss and beat revenue estimates in the third quarter of 2019. Onpattro continued to gain traction. The FDA set an action date of Feb 20, 2020. It showed strong commitment toward future pipeline growth through its landmark ocular and CNS disease alliance with Regeneron. The company also aims to expand the label of Onpattro for patients with cardiomyopathy and a potential label expansion should boost sales.The company’s efforts to develop its pipeline (inclisiran and lumasiran) are impressive. The company also expects to submit an NDA for inclisiran in 2019. Although we are pleased with Alnylam’s broad and promising pipeline, heavy dependence on Onpattro for growth is a concern. Moreover, the company heavily relies on its partnerships for supporting operations.Shares have outperformed the industry." (11/19/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $135 price target. Our small/mid-cap analyst Ellie Merle today launched coverage of Ionis (IONS, N). Ionis developed Onpattro competitor Tegsedi, which is now licensed to and commercialized by Akcea (AKCA, NC). We agree that Onpattro has taken meaningful share and that near-term competition from Tegsedi will likely be limited. Here we note relevant key takes from her launch and our perspective on the TTR market. We think that the overall TTR market opportunity is large, but that increasing diagnosis and treatment rates will take time." (4/9/2019)

Has Alnylam Pharmaceuticals been receiving favorable news coverage?

Media coverage about ALNY stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alnylam Pharmaceuticals earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Alnylam Pharmaceuticals.

Are investors shorting Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals saw a drop in short interest in November. As of November 29th, there was short interest totalling 5,530,000 shares, a drop of 12.1% from the November 14th total of 6,290,000 shares. Based on an average trading volume of 732,700 shares, the days-to-cover ratio is presently 7.5 days. Approximately 5.0% of the company's stock are sold short. View Alnylam Pharmaceuticals' Current Options Chain.

Who are some of Alnylam Pharmaceuticals' key competitors?

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), NXP Semiconductors (NXPI), Gilead Sciences (GILD), Mylan (MYL), Netflix (NFLX), Opko Health (OPK) and Celgene (CELG).

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the folowing people:
  • Dr. John M. Maraganore, CEO & Exec. Director (Age 56)
  • Mr. Barry E. Greene, Pres (Age 56)
  • Mr. Manmeet Singh Soni, Sr. VP, CFO & Principal Accounting Officer (Age 41)
  • Dr. Yvonne Greenstreet MBChB, MBA, Exec. VP & COO (Age 56)
  • Dr. Akshay K. Vaishnaw, Pres of R&D (Age 56)

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Maverick Capital Ltd. (2.89%), State Street Corp (2.69%), Gilder Gagnon Howe & Co. LLC (0.86%), First Trust Advisors LP (0.72%), Pictet Asset Management Ltd. (0.54%) and Sumitomo Mitsui Trust Holdings Inc. (0.39%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Michael Mason, Paul Schimmel, Philip A Sharp, Phillip A Sharp and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

Which institutional investors are selling Alnylam Pharmaceuticals stock?

ALNY stock was sold by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., First Trust Advisors LP, Coronation Fund Managers Ltd., Peregrine Capital Management LLC, Man Group plc, Alberta Investment Management Corp, Gilder Gagnon Howe & Co. LLC and Rhenman & Partners Asset Management AB. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Barry E Greene, John Maraganore, Marsha Fanucci, Philip A Sharp, Phillip A Sharp and Yvonne Greenstreet. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Which institutional investors are buying Alnylam Pharmaceuticals stock?

ALNY stock was bought by a variety of institutional investors in the last quarter, including Great Lakes Advisors LLC, State Street Corp, Sumitomo Mitsui Trust Holdings Inc., Millennium Management LLC, California Public Employees Retirement System, Parametric Portfolio Associates LLC, Pictet Asset Management Ltd. and Nisa Investment Advisors LLC. View Insider Buying and Selling for Alnylam Pharmaceuticals.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $117.74.

How big of a company is Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals has a market capitalization of $13.13 billion and generates $74.91 million in revenue each year. The biopharmaceutical company earns $-761,490,000.00 in net income (profit) each year or ($7.57) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,065 workers across the globe.View Additional Information About Alnylam Pharmaceuticals.

What is Alnylam Pharmaceuticals' official website?

The official website for Alnylam Pharmaceuticals is http://www.alnylam.com/.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]


MarketBeat Community Rating for Alnylam Pharmaceuticals (NASDAQ ALNY)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  925 (Vote Outperform)
Underperform Votes:  449 (Vote Underperform)
Total Votes:  1,374
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel